MCK Aktienübersicht
Die McKesson Corporation erbringt Dienstleistungen im Gesundheitswesen in den Vereinigten Staaten und international.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Narratives
BetaNarratives bring a range of perspectives from our community.
Warren
Based on Analyst Price Targets
Price at publication US$523.37
Updated
McKesson Corporation Wettbewerber
Preisentwicklung & Leistung
| Historical stock prices | |
|---|---|
| Current Share Price | US$589.95 |
| 52 Week High | US$592.41 |
| 52 Week Low | US$395.30 |
| Beta | 0.47 |
| 1 Month Change | 6.96% |
| 3 Month Change | 10.55% |
| 1 Year Change | 45.24% |
| 3 Year Change | 219.08% |
| 5 Year Change | 343.37% |
| Change since IPO | 3,475.45% |
Aktuelle Nachrichten und Updates
Recent updates
With McKesson Corporation (NYSE:MCK) It Looks Like You'll Get What You Pay For
May 09
Is McKesson Corporation (NYSE:MCK) Trading At A 43% Discount?
Mar 14McKesson: GLP-1 Contributed More Than 1/3 Of Growth
Feb 19McKesson's (NYSE:MCK) Profits May Not Reveal Underlying Issues
Feb 16Investor Optimism Abounds McKesson Corporation (NYSE:MCK) But Growth Is Lacking
Jan 29McKesson: Why The Company Is Too Richly Valued
Jan 19If EPS Growth Is Important To You, McKesson (NYSE:MCK) Presents An Opportunity
Nov 20McKesson: GLP-1 Medications Tailwinds And Massive Share Repurchase
Nov 08Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 44%?
Oct 30McKesson: Still Trading For A Huge Discount
Sep 06Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors
Aug 21Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 29%?
Jul 27McKesson: Outlook Remains Positive, I Reiterate My Buy Recommendation
Jun 28Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors
May 23Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 32%?
Apr 17Do McKesson's (NYSE:MCK) Earnings Warrant Your Attention?
Feb 22McKesson Corporation: Looking Forward To Long-Term Low-Teens EPS Growth
Feb 08McKesson Non-GAAP EPS of $6.90 beats by $0.54, revenue of $70.5B misses by $480M
Feb 01McKesson Corporation's (NYSE:MCK) Intrinsic Value Is Potentially 33% Above Its Share Price
Jan 125 Reasons Why I Am Considering Adding McKesson To My Portfolio
Dec 27McKesson Corporation: Still Trading Below Intrinsic Value
Dec 13Duration: The Time Bomb In Your Portfolio - McKesson And PayPal In Focus
Oct 08McKesson extends distribution partnership with CVS Health
Sep 29An Intrinsic Calculation For McKesson Corporation (NYSE:MCK) Suggests It's 50% Undervalued
Sep 19McKesson to acquire Rx Savings Solutions in $875M deal
Sep 19Cardinal Health, McKesson hit 52-week highs; up 35% and 50% YTD
Aug 15McKesson raises fiscal 2023 adjusted diluted EPS following strong quarterly results
Aug 03McKesson raises dividend by 15% to $0.54/share
Jul 25McKesson Is Still An Attractive Dividend Growth Stock
Jul 10McKesson: Best Of Breed In Drug Distributor Oligopoly
Jun 20Aktionärsrenditen
| MCK | US Healthcare | US Markt | |
|---|---|---|---|
| 7D | 0.5% | -0.01% | 1.2% |
| 1Y | 45.2% | 6.1% | 20.6% |
Rendite im Vergleich zur Industrie: MCK übertraf die Branche US Healthcare , die im vergangenen Jahr eine Rendite von 6.2 erzielte.
Rendite vs. Markt: MCK übertraf den Markt US, der im vergangenen Jahr eine Rendite von 25.6 erzielte.
Preisvolatilität
| MCK volatility | |
|---|---|
| MCK Average Weekly Movement | 2.1% |
| Healthcare Industry Average Movement | 6.5% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiler Aktienkurs: MCK hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.
Volatilität im Zeitverlauf: MCKDie wöchentliche Volatilität (2%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1833 | 48,000 | Brian Tyler | www.mckesson.com |
Die McKesson Corporation erbringt Dienstleistungen im Gesundheitswesen in den Vereinigten Staaten und international. Das Unternehmen ist in vier Segmenten tätig: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions und International.
McKesson Corporation's Grundlagenzusammenfassung
| MCK grundlegende Statistiken | |
|---|---|
| Marktanteil | US$76.83b |
| Gewinn(TTM) | US$3.00b |
| Umsatz(TTM) | US$308.95b |
25.5x
Kurs-Gewinn-Verhältnis0.2x
Kurs-Umsatz-VerhältnisIst MCK zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| MCK Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$308.95b |
| Kosten der Einnahmen | US$296.37b |
| Bruttogewinn | US$12.58b |
| Sonstige Ausgaben | US$9.58b |
| Umsatz | US$3.00b |
Zuletzt gemeldete Gewinne
Mar 31, 2024
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 23.09 |
| Bruttomarge | 4.07% |
| Nettogewinnspanne | 0.97% |
| Schulden/Eigenkapital-Verhältnis | -342.2% |
Wie hat sich MCK auf lange Sicht entwickelt?
Historische Performance und Vergleiche